NVO/N Stock Price and Chart — BMV:NVO/N

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Jefferies has reduced the target price for Novo Nordisk (NOVO_B) to DKK 415, down from the previous target of DKK 450.

KKR has exited a group aiming to acquire Gerresheimer AG, which produces injection pens for Novo Nordisk's Wegovy, previously valued at about 3.1 billion euros.

Novo Nordisk has reshuffled its executive team. Ludovic Helfgott will replace Camilla Sylvest as EVP of Commercial Strategy, while Thilde Hummel Bøgebjerg becomes EVP of Quality and IT.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.